Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06–0002 Study Update

Bertrand Coiffier, MD, PhD, Barbara Pro, MD, Miles Prince, MD, FRACP, FRCPA, Francine M. Foss, MD, Lubomir Sokol, MD, Ph.D, Matthew Greenwood, MD, FRACP, FRCPA, Dolores Caballero, MD, Franck Morschhauser, MD, PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, MD, Swaminathan Padmanabhan, MD, Andrei R. Shustov, MD, Tina Nielsen, MD, PhD, Jean Nichols, PhD, Julie Wolfson, MPH, Barbara E Balser, VMD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 3641.

https://doi.org/10.1182/blood.V120.21.3641.3641

Published: 2012

Journal Articles

Wilm's Tumor 1 Protein Confers TRAIL Resistance in Myeloid Leukemia Cells Through Bcl-Xl

Hima Bansal, PhD, Theresea Siefert, Divya Chakravarthy, Manjeet Rao, Gail E Tomlinson, MD, PhD, Swaminathan Padmanabhan, MD, Sanjay Bansal

Blood (2011) 118 (21): 2557.

https://doi.org/10.1182/blood.V118.21.2557.2557

Published: 2011

Journal Articles

A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma,

Carol A. Huff, MD, Swaminathan Padmanabhan, MD, Kevin R. Kelly, MD, George Somlo, MD, Luis Camacho, MD, MPH, Jeffrey Zonder, MD, Bruce Fischer, MD, Lixin Lang, Steven Zhang, Toni Gestone, Kelly L. Bennett

Blood (2011) 118 (21): 3993.

https://doi.org/10.1182/blood.V118.21.3993.3993

Published: 2011

Journal Articles

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

Michael Andreeff, MD, PhD, Kensuke Kojima, MD, PhD, Swaminathan Padmanabhan, MD, Roger Strair, MD, Mark Kirschbaum, MD, Peter Maslak, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Susan O'Brien, Felipe Samaniego, Gautam Borthakur, MD, Marina Konopleva, MD, PhD, Lyubomir Vassilev, PhD, Gwen Nichols, MD

Blood (2010) 116 (21): 657.

https://doi.org/10.1182/blood.V116.21.657.657

Published: 2010

Journal Articles

A New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Superior Specimens with Less Pain: Results of a Randomized Clinical Study

Ronan Swords, MD, MRCPI, FRCPath, Javier Anguita, MD, Russell A. Higgins, MD, Andrea Yunes, MD, Michael Naski, MD, PhD, Swaminathan Padmanabhan, MD, Kevin R Kelly, MD, Devalingam Mahalingam, MD, PhD, Thomas Philbeck, PhD, Larry Miller, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Marsha Kinney, MD, Andrew Brenner, MD

Blood (2010) 116 (21): 1529.

https://doi.org/10.1182/blood.V116.21.1529.1529

Published: 2010

Journal Articles

Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

Bertrand Coiffier, MD, PhD, Barbara Pro, MD, H. Miles Prince, MD, FRACP, FRCPA, Francine M Foss, MD, Lubomir Sokol, MD, PhD, Matthew Greenwood, MD, FRCPA, FRACP, Dolores Caballero, MD, Peter Borchmann, MD, Franck Morschhauser, MD, PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, MD, Swaminathan Padmanabhan, MD, Andrei Shustov, MD, Jean Nichols, Susan Carroll, John Balser, PhD, Steven M Horwitz, MD

Blood (2010) 116 (21): 114.

https://doi.org/10.1182/blood.V116.21.114.114

Published: 2010

Journal Articles

MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia.

Ronan T. Swords, M.D., Kevin R. Kelly, MD, Peter G. Smith, PhD, James J. Gansey, Devalingam Mahalingam, M.D., Swaminathan Padmanabhan, MD, MBBS, Michael C. O'Dwyer, MD, FRCPI, FRCPath, Steffan T. Nawrocki, PhD, Francis J. Giles, MD, Jennifer S. Carew, Ph.D.

Blood (2009) 114 (22): 1021.

https://doi.org/10.1182/blood.V114.22.1021.1021

Published: 2009

Journal Articles

The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine.

Kevin R. Kelly, MD, Ronan T. Swords, M.D., Devalingam Mahalingam, M.D., Steffan T. Nawrocki, PhD, Ernest Medina, B.S., Sabrina Smith, Swaminathan Padmanabhan, MD, MBBS, Jeffrey Ecsedy, Mary R Cahill, FRCPI, FRCPath, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jennifer S. Carew, Ph.D.

Blood (2009) 114 (22): 2087.

https://doi.org/10.1182/blood.V114.22.2087.2087

Published: 2009

Journal Articles

Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.

Steven M. Horwitz, MD, Julie M. Vose, M.D., Ranjana Advani, MD, Kamalesh Sankhala, MD, Swaminathan Padmanabhan, MD, Paul A. Hamlin, Jr., MD, Andy Chen, MD, PhD, Jasmine M Zain, MD, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 1674.

https://doi.org/10.1182/blood.V114.22.1674.1674

Published: 2009

Journal Articles

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

Swaminathan Padmanabhan, MD, MBBS, Joseph Thaddeus Beck, MD, Kevin R. Kelly, MD, Nikhil C. Munshi, MD, Andy Dzik-Jurasz, Esha Gangolli, Seth Ettenberg, Kelly Miner, Sanela Bilic, Winston Whyte, Fazal Mehdi, Lu-May Chiang, Patricia Liz Rae, BSc, Andrew Spencer, Jatin Shah, MD, Kenneth C. Anderson, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, A. Keith Stewart, MBChB

Blood (2009) 114 (22): 750.

https://doi.org/10.1182/blood.V114.22.750.750

Published: 2009

Journal Articles

Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.

Michael C O'Dwyer, MD, FRCPI, FRCPath, Emma Kent, Michael Parker, BSc, MSc, CStat, CMath, Ronan T. Swords, M.D., Frank Giles, MD, MB, FRCPI, FRCPath, Philipp le Coutre, MD, Swaminathan Padmanabhan, MD, MBBS, Brian Moulton, Ph.D, Mary Frances McMullin, Stephen Langabeer, PhD, Karine Egan, Ph.D, Eibhlin Conneally, MB, MRCP, MRCPath, PhD

Blood (2009) 114 (22): 3294.

https://doi.org/10.1182/blood.V114.22.3294.3294

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Fangxin Hong, PhD, Swaminathan Padmanabhan, MD, Ashraf Z. Badros, MD, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Edie Weller, PhD, Jeffrey Matous

Blood (2009) 114 (22): 2727.

https://doi.org/10.1182/blood.V114.22.2727.2727

Published: 2009

Journal Articles

Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.

Don Benson, MD, PhD, Craig C. Hofmeister, MD, Swaminathan Padmanabhan, MD, MBBS, Rafat Abonour, Attaya Suvannasankha, MD, Alain Mita, Patrick Squiban, MD, Megan K Smith, MS, CNP, RN, Courtney E Bakan, Marc Marzetto, Pascale Andre, PhD, Jerome Tollier, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 2880.

https://doi.org/10.1182/blood.V114.22.2880.2880

Published: 2009

Journal Articles

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Blood (2008) 112 (11): 328.

https://doi.org/10.1182/blood.V112.11.328.328

Published: 2008

Journal Articles

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, M.D., Jeffrey Matous, MD, Swaminathan Padmanabhan, MD, Ashraf Badros, MD, Robert Schlossman, MD, Stacey Chuma, RN, Renee Leduc1, Marybeth Nelson, PA, Kelly O’Connor, Amy Sam, Brianna Harris, Jacob Soumerai, Diane Warren, Ann Birner, Nikhil Munshi, MD, Steven P. Treon, MD, PhD, Kenneth C. Anderson, MD, Paul Richardson, MD

Blood (2008) 112 (11): 832.

https://doi.org/10.1182/blood.V112.11.832.832

Published: 2008

Journal Articles

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma.

Asher A. Chanan-Khan, MD, Kena C. Miller, NP, Dawn DePaolo, Swaminathan Padmanabhan, MD, Amy Whitworth, Sikander Ailawadhi, MD, Kelvin Lee, MD, Myron S. Czuczman, MD

Blood (2007) 110 (11): 3614.

https://doi.org/10.1182/blood.V110.11.3614.3614

Published: 2007

Journal Articles

Determining the Extent of Disease with Magnetic Resonance Imaging of the Bone Marrow (BM-MRI) in Patients with Multiple Myeloma (MM).

Sikander Ailawadhi, MD, Lyudmyla Derby, MD, Terry L. Mashtare, PhD, Kena C. Miller, MSN NP, Gregory Wilding, PhD, Swaminathan Padmanabhan, MD, Ronald Gottlieb, MD MPH, Ronald A. Alberico, MD, Donald L. Klippenstein, MD, Ahmed N. Abdelhalim, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 1483.

https://doi.org/10.1182/blood.V110.11.1483.1483

Published: 2007

Journal Articles

WT1 Interaction with the Chaperone Protein HSP90 Regulates Its Expression in Myeloid Leukemia.

Sanjay Bansal, PhD, Hima Bansal, PhD, Emre Baris, PhD, Elizabeth Repasky, PhD, Asher Chanan-Khan, MD, Kelvin P. Lee, MD, Swaminathan Padmanabhan, MD

Blood (2007) 110 (11): 1826.

https://doi.org/10.1182/blood.V110.11.1826.1826

Published: 2007

Journal Articles

bcl-2 Translocation [t(14;18) (q32;q21)] Does Not Correlate with Poor Clinical Outcome in Multiple Myeloma Patients Treated with Bortezomib.

Sikander Ailawadhi, MD, Terry L. Mashtare, PhD, Marie V. Coignet, Dawn M. DePaolo, Kena C. Miller, MSN, NP, Swaminathan Padmanabhan, MD, Gregory Wilding, PhD, Petr Starostik, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 1498.

https://doi.org/10.1182/blood.V110.11.1498.1498

Published: 2007

Journal Articles

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.

Swaminathan Padmanabhan, MD, Anjana Elefante, PharmD, Prakash Varadarajan, MD, Minoo Battiwalla, MD, Arvinder Bir, MD, Theresa Hahn, PhD, Shannon Smiley, MD, Francisco J. Hernandez-Illizalitturi, MD, Loretta Miner, RNP, Alice Mohr, RNP, Zale P. Bernstein, MD, Asher Chanan-Khan, MD, Philip McCarthy, Jr., MD, Myron Czuczman, MD

Blood (2007) 110 (11): 5130.

https://doi.org/10.1182/blood.V110.11.5130.5130

Published: 2007

NARROW

Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06–0002 Study Update

Wilm's Tumor 1 Protein Confers TRAIL Resistance in Myeloid Leukemia Cells Through Bcl-Xl

A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma,

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

A New Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Superior Specimens with Less Pain: Results of a Randomized Clinical Study

Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia.

The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine.

Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results.

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma.

Determining the Extent of Disease with Magnetic Resonance Imaging of the Bone Marrow (BM-MRI) in Patients with Multiple Myeloma (MM).

WT1 Interaction with the Chaperone Protein HSP90 Regulates Its Expression in Myeloid Leukemia.

bcl-2 Translocation [t(14;18) (q32;q21)] Does Not Correlate with Poor Clinical Outcome in Multiple Myeloma Patients Treated with Bortezomib.

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only